Emendo Biotherapeutics has achieved the first milestone under its alliance with Takeda Pharmaceutical Co., resulting in the transfer of the second half of the investment from Takeda to Emendo. Emendo has executed two agreements with Takeda, including an investment in convertible notes from Takeda Ventures, Inc., the corporate venture arm of Takeda and a licensing option agreement that grants Takeda the option to use OMNI, Emendo’s nuclease program to edit two genes as part of its R&...